Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2261
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study ; volume:21 ; number:1 ; day:21 ; month:9 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cardiovascular disorders ; 21, Heft 1 (21.9.2021), 1-11, 12.2021

Creator
Gamaza-Chulián, Sergio
Díaz-Retamino, Enrique
González-Testón, Fátima
Gaitero, José Carlos
Castillo, María José
Alfaro, Raquel
Rodríguez, Elías
González-Caballero, Eva
Martín-Santana, Antonio
Contributor
SpringerLink (Online service)

DOI
10.1186/s12872-021-02250-9
URN
urn:nbn:de:101:1-2021112919480415634257
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Gamaza-Chulián, Sergio
  • Díaz-Retamino, Enrique
  • González-Testón, Fátima
  • Gaitero, José Carlos
  • Castillo, María José
  • Alfaro, Raquel
  • Rodríguez, Elías
  • González-Caballero, Eva
  • Martín-Santana, Antonio
  • SpringerLink (Online service)

Other Objects (12)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Efficacy and Safety of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use during Ramadan Fasting: A Systematic Review

Efficacy and Safety of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use during Ramadan Fasting: A Systematic Review

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

Related objects